Vivos Therapeutics マネジメント

マネジメント基準チェック /44

Vivos Therapeuticsの CEO はR. Huntsmanで、 Sep2016年に任命され、の在任期間は 8.17年です。の年間総報酬は$ 657.70Kで、 70.5%給与と29.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.53%を直接所有しており、その価値は$ 215.53K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と4.4年です。

主要情報

R. Huntsman

最高経営責任者

US$657.7k

報酬総額

CEO給与比率	70.5%
CEO在任期間	8.2yrs
CEOの所有権	1.5%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	4.4yrs

経営陣の近況

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

CEO報酬分析

Vivos Therapeutics の収益と比較して、R. Huntsman の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$13m
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$658k	US$463k	-US$14m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$938k	US$385k	-US$24m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$1m	US$344k	-US$20m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$455k	US$252k	-US$18m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$12m
Dec 31 2019	US$328k	US$249k	-US$12m
Dec 31 2018	US$284k	US$249k	-US$9m

報酬と市場: R.の総報酬 ($USD 657.70K ) は、 US市場 ($USD 650.80K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: R.の報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

R. Huntsman (66 yo)

8.2yrs

在職期間

US$657,701

報酬

Mr. R. Kirk Hunstman is the Co-Founder of Vivos Therapeutics, Inc. since September 2016 and has been its Chief Executive Officer and Director since September 2016 and has been its Chairman of the Board sin...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
R. Huntsman	Co-Founder	8.2yrs	US$657.70k	1.53% $ 215.5k
Bradford Amman	CFO, Treasurer & Secretary	6.1yrs	US$400.04k	0.0017% $ 236.2
Todd Huntsman	Co-Founder & Senior VP of Product and Technology	less than a year	データなし	データなし
RaeAnn Byrnes	Co-Founder and Senior VP of Events & Clinical Advisory Services	no data	データなし	データなし
Susan McCullough	Co-Founder & Executive VP of Operations	less than a year	データなし	データなし
Nicholas DeGennaro	Senior Vice President of Medical Integration Division	5.1yrs	データなし	データなし
Ruth Hembree	Senior Vice President of Practice Services	no data	データなし	データなし
Stephanie Huebner	Senior Vice President of Dental Service Integration	2.8yrs	データなし	データなし
John Ballard	Senior Vice President of Technology	less than a year	データなし	データなし

2.8yrs

平均在職期間

経験豊富な経営陣: VVOSの経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
R. Huntsman	Co-Founder	8.2yrs	US$657.70k	1.53% $ 215.5k
Leonard Sokolow	Independent Director	4.4yrs	US$63.00k	0.0084% $ 1.2k
Anja Krammer	Independent Director	4.4yrs	US$58.00k	0% $ 0
Mark Lindsay	Independent Director	4.4yrs	US$58.00k	0% $ 0
Matthew Thompson	Independent Director	4.4yrs	US$63.00k	0% $ 0
Edward Zuckerberg	Member of Medical & Clinical Advisory Board	3.8yrs	データなし	データなし
Ralph Green	Independent Director	4.4yrs	US$58.00k	0% $ 0
Michael Gelb	Member of Medical & Clinical Advisory Board	3.8yrs	データなし	データなし
Manisha Witmans	Member of Medical & Clinical Advisory Board	3.8yrs	データなし	データなし
Tammarie Heit	Member of Medical & Clinical Advisory Board	3.8yrs	データなし	データなし
Clete Kushida	Co-Chair of Medical & Clinical Advisory Board	3.8yrs	データなし	データなし
Cecilia Wu	Co-Chair of Medical & Clinical Advisory Board	no data	データなし	データなし

4.4yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: VVOSの取締役会は経験豊富であると考えられます ( 4.4年の平均在任期間)。

Vivos Therapeutics マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Vivos Therapeutics, Inc., Annual General Meeting, Nov 26, 2024

High number of new and inexperienced directors

Vivos Therapeutics, Inc., Annual General Meeting, Sep 22, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Vivos Therapeutics, Inc., Annual General Meeting, Aug 25, 2022

Recent updates

Consensus EPS estimates upgraded to US$2.02 loss, revenue downgraded

Price target decreased by 14% to US$6.30

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Vivos Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc., Annual General Meeting, Nov 26, 2024

New major risk - Share price stability

Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Consensus estimates of losses per share improve by 31%

New major risk - Financial position

Vivos Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Vivos Therapeutics Announces Positive Results from 7-Month Multi-Site Pilot of Its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics, Inc. announced that it has received $7.5 million in funding

Vivos Therapeutics Provides Non-Compliance Update

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Vivos Therapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Vivos Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Vivos Therapeutics, Inc. Receives FDA Clearance to Vivos Care Oral Appliances to Treat Severe OSA in Adults

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Vivos Therapeutics, Inc. Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Vivos Therapeutics, Inc. Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.7% to US$45.00

High number of new and inexperienced directors

Vivos Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Vivos Therapeutics, Inc. announced that it has received $4.000003 million in funding

Vivos Therapeutics, Inc. announced that it expects to receive $4.000003 million in funding

Vivos Therapeutics Provides Nasdaq Compliance Update

Vivos Therapeutics Receives a Written Notice from the Nasdaq

Vivos Therapeutics, Inc., Annual General Meeting, Sep 22, 2023

Vivos Therapeutics Receives Non-Compliance Letterer from Nasdaq

Vivos Therapeutics, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Vivos Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Vivos Therapeutics, Inc. to Report Q1, 2023 Results on Jun 08, 2023

Vivos Therapeutics Receives Staff Deficiency Notice from The Nasdaq Stock Market Due to Failure to File its Form 10-Q

Vivos Therapeutics, Inc. announced delayed 10-Q filing

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Consensus EPS estimates upgraded to US$0.40 loss

Price target decreased by 17% to US$1.88

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.26 loss in 3Q 2021)

Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements

Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance of its DNA Oral Appliance for Treatment of Obstructive Sleep Apnea

Vivos Therapeutics, Inc. to Report Q3, 2022 Results on Dec 20, 2022

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Vivos Therapeutics Receives a Staff Deficiency Notice from The Nasdaq Stock Market

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Vivos Therapeutics again delays Q2 2022 results

Vivos Therapeutics, Inc. announced delayed 10-Q filing

Vivos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Vivos Therapeutics, Inc. Receives Multiple Class I Clearances by Therapeutic Goods Administration (TGA) of Australia

Vivos Therapeutics, Inc., Annual General Meeting, Aug 25, 2022

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Vivos Therapeutics, Inc. Presents Positive Results from a Retrospective Study with Vivos Patients

Consensus revenue estimates fall by 25%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$9.00

High number of new and inexperienced directors

No longer forecast to breakeven

マネジメント基準チェック /44